PSA Pharma: Santen Pharmaceutical (4536 JT) Initiation – Looking into the Future
In this initiation report, Nia Dokova reviews Santen’s recent performance under new-ish CEO Takeshi Ito, and lays out why the shares could be of interest to both growth and value investors at its current price.Santen Pharmaceutical is a pharmaceutical company engaged in the research and development, production and marketing of pharmaceuticals and medical devices. Co. operations in Japan, U.S., Europe and Asia, and sells products in over 50 countries. Co. offcer prescription ophthalmic pharmaceutical products, such as treatments for corneal and conjunctival epithelial disorders, glaucoma, anti-infective ophthalmics and anti-allergy ophthalmics. Co. also officers Over-the-Counter (OTC) Pharmaceuticals including eye drops. Additionally, Co. provides ophthalmic medical devices used in cataract surgery, and cleaning services for sterilized clothes.
Founded in 2009, Pelham Smithers Associates (PSA) provides market intelligence on Asian technology, focusing in particular on Japan. The industries covered by our team of specialists are: consumer electronics, telecomms, pharmaceuticals, internet, electronic parts and materials, automotive technology, retail and capital goods.
PSA produces both company and sector reports. The focus of PSA’s research is to identify winners and losers as new technologies impact the top and bottom lines of corporations. Critical to our research is the clear explanation of how these new technologies work and how they impact companies and industries.
The founding partners have worked closely together for twenty years and the team has more than doubled in size since 2012.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.